TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT

CONCLUSION: Taken together, these results demonstrate that DOCK1 may function as a potential therapeutic target in BC and that combining cisplatin with TBOPP may provide a promising therapeutic strategy for cisplatin-resistant BC patients.PMID:38415469 | DOI:10.2174/0115680096281231240202073558

Source: Current Cancer Drug Targets - February 28, 2024 Category: Cancer & Oncology Authors: Xin Chen Zhenbang Zhou Pengting Tang Feiya Du Shuqian Wang Jia Yao Shufen Zhang Jiajing Huang Xuemei Lu Wei Chen Xiaofang Yu Yu Liu Hao Liu Source Type: research